Specific oncogene activation of the cell of origin in mucosal melanoma

Swathy Babu, Jiajia Chen, Emily Robitschek, Chloé S. Baron, Alicia M. McConnell, Constance Wu, Aikaterini Dedeilia, Moshe Sade-Feldman, Rodsy Modhurima, Michael P. Manos, Kevin Y. Chen, Anna M. Cox, C Ludwig, Jiekun Yang, Manolis Kellis, Elizabeth I. Buchbinder, Nir Hacohen, Genevieve M. Boland, Brian J. Abraham, David Liu, Leonard I. Zon, Megan L. Insco

Abstract

Mucosal melanoma (MM) is a highly aggressive cancer derived from mucosal melanocytes, characterized by poor prognosis and resistance to conventional therapies. To investigate the genetic and cellular drivers of this disease, we developed a novel zebrafish model utilizing the MAZERATI system to express human CCND1 alongside the loss of PTEN and TP53. Despite these genetic alterations being present in all melanocytes, tumors developed exclusively from internal melanocytes, mirroring the anatomical distribution of human MM. Our findings reveal that MM arises from a unique cell state defined by a specific chromatin landscape and a gene expression signature shared with migratory neural crest cells. This state is characterized by decreased antigen presentation and independence from MAPK signaling, explaining the clinical challenges of immunotherapy resistance and BRAF-inhibitor insensitivity. This model provides a robust platform for the discovery of targeted therapeutics for mucosal melanoma.

Introduction

While cutaneous melanoma (CM) is often associated with ultraviolet (UV) radiation and BRAF mutations, mucosal melanoma (MM) is a distinct and far more deadly subtype. Arising in the internal linings of the body—such as the nasal cavity, oral mucosa, and anorectal tract—MM accounts for a small fraction of melanoma cases but carries a dismal 5-year survival rate of approximately 27%.

MM is biologically divergent from skin cancer in several key ways: it lacks UV-induced mutational signatures, is driven by large-scale structural genomic rearrangements (such as CCND1 amplification), and frequently fails to respond to the immune checkpoint inhibitors that have transformed CM treatment. Progress in understanding MM has been hindered by a lack of animal models that accurately reflect its unique genetics and internal origins.

A New Zebrafish Model for MM

To bridge this gap, researchers employed the MAZERATI system (Melanoma Analysis by Zebrafish Rapid Transgenic Integration) to create the first genetically engineered zebrafish model for MM. The model targets melanocytes with a "triple hit" of genetic alterations common in human patients:

  • Overexpression of human CCND1: A key cell cycle regulator frequently amplified in MM.
  • CRISPR-mediated deletion of PTEN: A critical tumor suppressor.
  • CRISPR-mediated deletion of TP53: The "guardian of the genome."

Using transparent "Casper" zebrafish, the team monitored tumor initiation. Remarkably, although the genetic drivers were introduced into all melanocytes, tumors only developed from internal melanocytes lining the organs. This suggests that the internal "cell state" is uniquely susceptible to transformation by these specific oncogenes.

The "Cell of Origin" and Molecular Identity

The study integrated bulk RNA-seq, single-cell RNA-seq (scRNA-seq), and ATAC-seq to compare internal and cutaneous melanocytes in both zebrafish and humans. Several key insights emerged regarding the identity of MM:

1. The TFAP2 Switch

The researchers identified a molecular divergence between the two melanoma types. While skin melanocytes rely on the transcription factor tfap2a, internal mucosal melanocytes and MM tumors express tfap2b. This suggests that MM arises from a more primitive, stem-like population of cells.

2. Neural Crest Reversion

Both fish and human MMs show an upregulation of genes associated with migratory neural crest cells—the embryonic precursors of melanocytes. This "reversion" to an embryonic state likely explains the high metastatic potential of MM, as the cells regain the ability to migrate throughout the body.

3. Intrinsic Immune Evasion

A major hurdle in treating MM is its resistance to immunotherapy. The study found that MM cells have naturally low levels of MHC Class I molecules, which are essential for the immune system to recognize and attack cancer cells. Crucially, this low expression is not just an acquired trait of the cancer; it is an intrinsic feature of the internal melanocytes from which the tumors originate.

Results and Clinical Implications

The CCND1; pten-/-; tp53-/- zebrafish developed internal tumors with an 11% penetrance, successfully mimicking the location and histology of human MM. Notably, these tumors exhibited low MAPK signaling activity (pERK), confirming why standard BRAF inhibitors—which target the MAPK pathway in skin cancers—are largely ineffective for MM patients.

Furthermore, the study identified PAX3 as a master regulator that maintains the internal melanocyte state. Overexpressing human PAX3 in zebrafish was sufficient to expand the population of these internal "cells of origin," providing a potential target for future intervention.

Conclusion and Future Directions

This zebrafish model provides a critical tool for understanding the unique biology of mucosal melanoma. By demonstrating that the cell of origin dictates the behavior and treatment response of the resulting tumor, the research highlights why MM must be treated as a distinct entity from skin cancer.

The next phase of research involves using this "fish-to-human" platform for high-throughput therapeutic discovery. By screening for compounds that can force MM cells to express MHC Class I or target the specific tfap2b/PAX3 cell state, researchers hope to identify new strategies to overcome the treatment resistance that makes this cancer so lethal.

Summary updated

Abstract

Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we developed a zebrafish model in which all melanocytes experienced CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only developed from melanocytes lining internal organs, analogous to the location of patient MM. We found that zebrafish MMs had a unique chromatin landscape from cutaneous melanoma. Internal melanocytes could be labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes shared a gene expression signature with MMs. Patient and zebrafish MMs have increased migratory neural crest gene and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery.
BibTeX
@inproceedings{babu2025specific,
  author = {Swathy Babu and Jiajia Chen and Emily Robitschek and Chloé S. Baron and Alicia M. McConnell and Constance Wu and Aikaterini Dedeilia and Moshe Sade-Feldman and Rodsy Modhurima and Michael P. Manos and Kevin Y. Chen and Anna M. Cox and C Ludwig and Jiekun Yang and Manolis Kellis and Elizabeth I. Buchbinder and Nir Hacohen and Genevieve M. Boland and Brian J. Abraham and David Liu and Leonard I. Zon and Megan L. Insco},
  title = {{Specific oncogene activation of the cell of origin in mucosal melanoma}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-61937-1},
}
Figure